An Israeli start-up based in Caesarea found a completely new approach to fighting tumors. No wonder, it didn’t take long to be found by investors. The fight against cancer mobilizes millions. Read more on VonNaftali: Subscription $29,90/12 months (net).
IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer.
Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared to-date by the U.S. Food and Drug Administration and approved in Europe with the CE Mark.
IceCure announced the closing of its previously announced “best efforts” public offering of 8,787,880 shares of the Company’s ordinary shares (the “Ordinary Shares“) priced at-the-market under Nasdaq rules at a price to the public of $1.65 per share. The gross proceeds of the offering to the Company were approximately $14.5 million, before deducting placement agent fees, commissions, and other estimated offering expenses.
Based on pressrelease by IceCure, selected as relevant, adapted, shortened and regrouped by VonNaftali.
VonNaftali/מנפּתלי/ByNaftali 